EP3544597A4 - Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions - Google Patents

Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions Download PDF

Info

Publication number: EP3544597A4
Authority: EP; European Patent Office
Prior art keywords: lidocaine; ineffective; therapies; treatment; hypokalemic
Prior art date: 2016-11-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP17874227.6A

Other languages

German (de)

French (fr)

Other versions

EP3544597A1 (en

Inventor

Michael M. SEGAL

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Alkalidx Inc

Original Assignee

Alkalidx Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-11-22

Filing date

2017-11-22

Publication date

2020-06-17

2017-11-22 Application filed by Alkalidx Inc filed Critical Alkalidx Inc

2019-10-02 Publication of EP3544597A1 publication Critical patent/EP3544597A1/en

2020-06-17 Publication of EP3544597A4 publication Critical patent/EP3544597A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Inorganic Chemistry (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Endocrinology (AREA)
Anesthesiology (AREA)
Psychiatry (AREA)
Mycology (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
Zoology (AREA)
Physiology (AREA)
Obesity (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP17874227.6A 2016-11-22 2017-11-22 Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions Withdrawn EP3544597A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662425512P	2016-11-22	2016-11-22
US201762449799P	2017-01-24	2017-01-24
PCT/US2017/063009 WO2018098273A1 (en)	2016-11-22	2017-11-22	Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions

Publications (2)

Publication Number	Publication Date
EP3544597A1 EP3544597A1 (en)	2019-10-02
EP3544597A4 true EP3544597A4 (en)	2020-06-17

Family

ID=62195652

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17874227.6A Withdrawn EP3544597A4 (en)	2016-11-22	2017-11-22	Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions

Country Status (13)

Country	Link
US (1)	US20190365799A1 (en)
EP (1)	EP3544597A4 (en)
JP (1)	JP2019535758A (en)
KR (1)	KR20190086712A (en)
CN (1)	CN110191706A (en)
AU (1)	AU2017363250A1 (en)
BR (1)	BR112019010077A2 (en)
CA (1)	CA3044573A1 (en)
IL (1)	IL266726A (en)
MX (1)	MX2019005851A (en)
PH (1)	PH12019501129A1 (en)
RU (1)	RU2019118985A (en)
WO (1)	WO2018098273A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9675587B2 (en)	2013-03-14	2017-06-13	Allergan Holdings Unlimited Company	Opioid receptor modulator dosage formulations
WO2021071902A1 (en) *	2019-10-10	2021-04-15	Brillian Pharma Inc.	Micronized drug resinate-based pharmaceutical compositions and methods of preparation thereof
CA3179754A1 (en) *	2020-04-08	2021-10-14	Tonix Pharmaceuticals Holding Corp.	Cyclobenzaprine treatment for sexual dysfunction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1029305A (en) *	1974-01-31	1978-04-11	Johanna Bickel	Infusion solution for the treatment of tachycardiac disturbances of heart rhythm and use thereof
US4988513A (en) *	1990-01-09	1991-01-29	Monsanto Company	Method of treating hypokalemia
US6780437B2 (en) *	2001-10-23	2004-08-24	Upsher-Smith Laboratories, Inc.	Coated potassium chloride granules and tablets
WO2006104703A1 (en) *	2005-03-29	2006-10-05	Mcneil-Ppc, Inc.	Compositions with hydrophilic drugs in a hydrophobic medium
EP1880716A1 (en) *	2006-07-19	2008-01-23	Sandoz AG	Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
US9085508B2 (en) *	2008-09-24	2015-07-21	Oral Delivery Technology Ltd.	Nitric oxide releasing amino acid ester compound, composition and method of use
UA114074C2 (en) *	2010-07-12	2017-04-25		Crystalline form with romidepsin and its use for the treatment of cutaneous T-cell lymphoma or peripheral T-cell lymphoma
WO2016022989A2 (en) *	2014-08-08	2016-02-11	The General Hospital Corporation	Systems and methods for monitoring and controlling a cardiovascular state of a subject

2017
- 2017-11-22 WO PCT/US2017/063009 patent/WO2018098273A1/en not_active Ceased
- 2017-11-22 RU RU2019118985A patent/RU2019118985A/en not_active Application Discontinuation
- 2017-11-22 CN CN201780084091.3A patent/CN110191706A/en active Pending
- 2017-11-22 MX MX2019005851A patent/MX2019005851A/en unknown
- 2017-11-22 AU AU2017363250A patent/AU2017363250A1/en not_active Abandoned
- 2017-11-22 EP EP17874227.6A patent/EP3544597A4/en not_active Withdrawn
- 2017-11-22 CA CA3044573A patent/CA3044573A1/en not_active Abandoned
- 2017-11-22 US US16/349,824 patent/US20190365799A1/en not_active Abandoned
- 2017-11-22 JP JP2019527446A patent/JP2019535758A/en active Pending
- 2017-11-22 KR KR1020197017131A patent/KR20190086712A/en not_active Withdrawn
- 2017-11-22 BR BR112019010077A patent/BR112019010077A2/en not_active Application Discontinuation
2019
- 2019-05-19 IL IL266726A patent/IL266726A/en unknown
- 2019-05-21 PH PH12019501129A patent/PH12019501129A1/en unknown

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"What causes ADHD? Some intriguing findings", INTERNET CITATION, 11 January 2008 (2008-01-11), pages 1 - 23, XP002789311, Retrieved from the Internet <URL:https://healthbusinessgroup.com/2008/01/what-causes-adhd-some-intriguing-findings/> [retrieved on 20190226] *
MATTHEW GRISSINGER: "Adding Lidocaine to IV Potassium Infusions Can Cause Safety Problems", P & T PHARMACY AND THERAPEUTICS JOURNAL, vol. 33, no. 2, 1 February 2008 (2008-02-01), US, pages 70 & 75, XP055695326, ISSN: 1052-1372 *
MICHAEL M. SEGAL ET AL: "Hypokalemic Sensory Overstimulation", JOURNAL OF CHILD NEUROLOGY., vol. 22, no. 12, 1 December 2007 (2007-12-01), CA, pages 1408 - 1410, XP055560962, ISSN: 0883-0738, DOI: 10.1177/0883073807307095 *
MICHAEL M. SEGAL: "We Cannot Say Whether Attention Deficit Hyperactivity Disorder Exists, but We Can Find Its Molecular Mechanisms", PEDIATRIC NEUROLOGY., vol. 51, no. 1, 1 July 2014 (2014-07-01), NL, pages 15 - 16, XP055560964, ISSN: 0887-8994, DOI: 10.1016/j.pediatrneurol.2014.04.014 *
See also references of WO2018098273A1 *

Also Published As

Publication number	Publication date
PH12019501129A1 (en)	2019-08-19
RU2019118985A (en)	2020-12-25
KR20190086712A (en)	2019-07-23
IL266726A (en)	2019-08-29
MX2019005851A (en)	2019-10-07
CA3044573A1 (en)	2018-05-31
US20190365799A1 (en)	2019-12-05
AU2017363250A1 (en)	2019-06-06
EP3544597A1 (en)	2019-10-02
CN110191706A (en)	2019-08-30
BR112019010077A2 (en)	2019-10-01
JP2019535758A (en)	2019-12-12
WO2018098273A1 (en)	2018-05-31

Publication	Publication Date	Title
IL265215B (en)	2022-06-01	Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
EP3191100A4 (en)	2018-05-30	Cenicriviroc combination therapy for the treatment of fibrosis
EP3212137A4 (en)	2018-11-14	Systems and methods for the treatment of eye conditions
EP3468973A4 (en)	2020-02-26	Solid forms of venetoclax and processes for the preparation of venetoclax
SG11201609770TA (en)	2016-12-29	Combination therapies for the treatment of cancer
EP3151797A4 (en)	2018-01-31	Methods and devices for treating the skin
EP3160405A4 (en)	2018-03-14	Treatment of the ear
EP3206497A4 (en)	2018-06-06	Compositions and methods for the treatment of meibomian gland dysfunction
EP3286311A4 (en)	2018-11-21	Method for the treatment of malignancies
EP3307240A4 (en)	2018-12-19	Combination therapy for the treatment of cancer
EP3119401A4 (en)	2017-12-13	Cenicriviroc for the treatment of fibrosis
EP3183005A4 (en)	2018-01-10	Methods and compositions for the treatment of metabolic disorders
EP3242947A4 (en)	2018-08-08	Method for the treatment of malignancies
EP3490561A4 (en)	2020-04-08	Combinations for the treatment of cancer
EP3157336A4 (en)	2018-01-24	Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
EP3538075A4 (en)	2020-08-05	Structures and methods for gene therapy
EP3429584A4 (en)	2019-11-13	Compositions and methods for the treatment of presbyopia
EP3419959A4 (en)	2019-10-23	Combination therapy
EP3503887A4 (en)	2020-05-06	Combinations for the treatment of cancer
EP3171881A4 (en)	2018-01-10	Treatment and prevention of the common cold using povidone-iodine
EP3185910A4 (en)	2018-01-10	Methods and compositions for the treatment of cancer
EP3134108A4 (en)	2018-01-17	Agents and methods of treatment
EP3122349A4 (en)	2017-10-11	Compositions for the treatment of autodigestion
EP3548007A4 (en)	2020-08-12	Methods for the treatment of cancer
EP3256124A4 (en)	2018-09-26	Cenicriviroc for the treatment of fibrosis

Legal Events

Date	Code	Title	Description
2018-06-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2019-08-30	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2019-08-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-10-02	17P	Request for examination filed	Effective date: 20190521
2019-10-02	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-10-02	AX	Request for extension of the european patent	Extension state: BA ME
2020-02-26	DAV	Request for validation of the european patent (deleted)
2020-02-26	DAX	Request for extension of the european patent (deleted)
2020-06-17	A4	Supplementary search report drawn up and despatched	Effective date: 20200520
2020-06-17	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/215 20060101ALI20200514BHEP Ipc: A61P 5/00 20060101ALI20200514BHEP Ipc: A61K 33/14 20060101ALI20200514BHEP Ipc: A61K 45/06 20060101ALI20200514BHEP Ipc: A61P 25/00 20060101ALI20200514BHEP Ipc: A61P 25/18 20060101ALI20200514BHEP Ipc: A61K 31/045 20060101AFI20200514BHEP Ipc: A61P 43/00 20060101ALI20200514BHEP Ipc: A61P 25/02 20060101ALI20200514BHEP Ipc: A61P 25/24 20060101ALI20200514BHEP Ipc: A61K 31/191 20060101ALI20200514BHEP Ipc: A61P 23/02 20060101ALI20200514BHEP Ipc: A61P 3/12 20060101ALI20200514BHEP
2021-05-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2021-06-16	18D	Application deemed to be withdrawn	Effective date: 20201222